| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AC55649 | CTRPv2 | pan-cancer | AAC | 0.0063 | 0.9 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0054 | 0.9 |
| mRNA | simvastatin | CTRPv2 | pan-cancer | AAC | 0.0064 | 0.9 |
| mRNA | BRD-K52037352 | CTRPv2 | pan-cancer | AAC | 0.0066 | 0.9 |
| mRNA | BRD-K92856060 | CTRPv2 | pan-cancer | AAC | 0.0059 | 0.9 |
| mRNA | prochlorperazine | CTRPv2 | pan-cancer | AAC | -0.0059 | 0.9 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | -0.0047 | 0.9 |
| mRNA | OSI-027 | GDSC1000 | pan-cancer | AAC | 0.0047 | 0.9 |
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | 0.0054 | 0.9 |
| mRNA | CID-5951923 | CTRPv2 | pan-cancer | AAC | -0.0055 | 0.9 |